Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10457153 | 0.73 | CYP2C9 (0.42) | CYP2C9 | |
| SCHEMBL1726623 | 0.69 | CYP2C9 (0.38) | CYP2C9 | |
| SCHEMBL12420559 | 0.69 | CYP2C9 (0.38) | CYP2C9 | |
| SCHEMBL12508912 | 0.69 | CYP2C9 (0.38) | CYP2C9 | |
| SCHEMBL871897 | 0.69 | CYP2C9 (0.38) | CYP2C9HSD17B10L3MBTL1 | |
| SCHEMBL5145782 | 0.65 | — | — | |
| SCHEMBL631518 | 0.63 | EPHX2 (0.41) | CYP2C9HSD17B10L3MBTL1 | |
| SCHEMBL11033574 | 0.62 | CYP2C9 (0.44) | CYP2C9 | |
| Adamantane SCHEMBL28785912 | 0.62 | CYP2C9 (0.40) | CYP2C9 | |
| Adamantane SCHEMBL1527414 | 0.61 | CYP2C9 (0.46) | CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0607334-B1 | CYCLIC UREAS AND ANALOGUES USEFUL AS RETROVIRAL PROTEASE INHIBITIORS | DU PONT MERCK PHARMA (US) | 1997-07-30 | — | — | EP | claimed |
| CN-115551504-B | Novel pharmacological chaperones of human acid alpha-glucosidase and therapeutic uses thereof | 格勒诺布尔-阿尔卑斯大学 | 2024-12-13 | — | — | CN | disclosed |
| US-20230339856-A1 | NOVEL PHARMACOLOGICAL CHAPERONE COMPOUNDS OF HUMAN ACID ALPHA-GLUCOSIDASE AND THE THERAPEUTIC USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-10-26 | — | — | US | disclosed |
| EP-4138827-A1 | NOVEL PHARMACOLOGICAL CHAPERONE COMPOUNDS OF HUMAN ACID ALPHA-GLUCOSIDASE AND THE THERAPEUTIC USE THEREOF | Université Grenoble Alpes (FR) | 2023-03-01 | — | — | EP | disclosed |
| WO-2021214245-A1 | NOVEL PHARMACOLOGICAL CHAPERONE COMPOUNDS OF HUMAN ACID ALPHA-GLUCOSIDASE AND THE THERAPEUTIC USE THEREOF | UNIVERSITÉ GRENOBLE ALPES (FR) | 2021-10-28 | — | — | WO | disclosed |
| US-20090030248-A1 | Ethynylphenylbiadamantane derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-2014636-A1 | Ethynylphenylbiadamantane derivatives | Daicel Chemical Industries, Ltd. (JP) | 2009-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030248-A1 | Ethynylphenylbiadamantane derivatives | CHRNA5, CHRNE, ADRA1D | CYP2C9 271/4885HSD17B10 1922/4885L3MBTL1 3002/4885 |
| US-20230339856-A1 | NOVEL PHARMACOLOGICAL CHAPERONE COMPOUNDS OF HUMAN ACID ALPHA-GLUCOSIDASE AND THE THERAPEUTIC USE THEREOF | GAA, GBA3, GANAB | CYP2C9 3849/4885HSD17B10 2056/4885L3MBTL1 3724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.